WntResearch announces last patient initiated treatment in the clinical phase 1 study

WntResearch today announces that the last patient has initiated treatment on the last dose level (dose level 8) in their on-going clinical phase 1 study with Foxy-5.

Nils Brünner, CEO says, ”I am very satisfied that we have identified, enrolled and started to treat the last patient in our phase 1 study with Foxy-5. During Q4, as the results of the complete study are analysed, we will present a summary report containing the available data from the study”.

Nils Brünner continues, “Meanwhile, we are finalising the study protocol for the phase 1b study, which we aim to initiate as soon as possible. We are also continuing our work planning for the upcoming phase 2 study”.

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.